Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study
Headache: The Journal of Head and Face Pain,  Clinical Article

Derosier F et al. – This study primarily included subjects whose migraines significantly impacted their lives. Before the study, these subjects used butalbital–containing medications as part of their current migraine treatment regimen and were satisfied with it, suggesting they were butalbital responders who had found a workable treatment strategy for themselves. When treated with SumaRT/Nap versus BCM in this study, however, a significant proportion of subjects reported better treatment outcomes for themselves for both migraine pain and associated symptoms. Use of SumaRT/Nap was also associated with less rescue medication use and a longer time before use of rescue medication compared with both BCM and placebo.

Methods
  • Enrolled subjects were required to have treated at least 1 migraine with a butalbital medication in the past.
  • Enrolled subjects treated 3 moderate to severe migraines using each of the 3 study treatments once in a randomized sequence.
  • The primary endpoint compared SumaRT/Nap versus BCM for sustained pain freedom at 2–24 hours without the use of any rescue medication.
  • This study combines data from 2 identical outpatient, randomized, multicenter, double–blind, double–dummy, 3 attack crossover studies in adult migraineurs (International Classification of Headache Disorders, 2nd edition).

Results
  • A total of 442 subjects treated at least 1 attack with study medication.
  • The majority of the treated subjects were female (88%) with a mean age 43 years, who reported that their migraines had a severe impact on their lives (78% with Headache Impact Test–6 of >59).
  • At screening, 88% of subjects reported current butalbital use; 68% had used butalbital for more than 6 weeks; and 82% reported satisfaction with butalbital.
  • Across treatment groups, 28–29% of subjects took study medication within 15 minutes of migraine onset, 34–37% of subjects took study medication >15 minutes to 2 hours after onset, and 32–36% of subjects took study medication more than 2 hours after onset.
  • This study did not detect a difference at the nominal 0.05 level in percent sustained pain–free between SumaRT/Nap (8%), BCM (6%), and placebo (3%).
  • SumaRT/Nap was superior to BCM for pain free at 2, 4, 6, 8, 24, 48 hours (P ≤ .044); pain relief (mild or no pain) at 2, 4, 6, 8, 24, 48 hours (P ≤ .01); sustained pain relief 2–24 hours (P < .001); migraine free (pain free with no nausea, photophobia, or phonophobia) at 4, 6, 8, 24, 48 hours (P ≤ .046); and complete symptom free (migraine free with no neck/sinus pain) at 4, 6, 8, 48 hours (P ≤ .031).
  • Adverse event incidence was similar for all treatments (10%, 12%, and 9% for placebo, SumaRT/Nap, and BCM, respectively).
  • Nausea was the most frequent adverse event (2%, 2%, and <1% for placebo, SumaRT/Nap, and BCM, respectively).
  • Five serious adverse events were reported by 3 subjects: viral meningitis and colon neoplasm (placebo); chest pain and hypertension 17 days postdose (SumaRT/Nap); and breast cancer (BCM).
  • Investigators judged no serious adverse events related to study medication.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Neurology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Neurology Articles

1 Clopidogrel plus aspirin aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke Journal of Clinical Neuroscience, November 13, 2014    Clinical Article

2 Marijuana use associated with lower death rates in patients with traumatic brain injuries Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center News, November 11, 2014

3 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

4 Effects of antiplatelet agents on functional outcome and cognitive status in patients with acute ischemic stroke Full Text International Journal of Gerontology, November 21, 2014    Free full text    Clinical Article

5 Efficacy and safety of novel oral anticoagulants in patients with cervical artery dissections Cerebrovascular Diseases, November 14, 2014    Clinical Article

6 Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial Cerebrovascular Diseases, October 16, 2014    Clinical Article

7 Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial The Lancet, October 17, 2014    Evidence Based Medicine    Clinical Article
Exclusive Author Commentary

8 Antithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation Stroke, November 25, 2014    Clinical Article

9 Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals International Journal of Cardiology, November 7, 2014    Clinical Article

10 Menopausal hormone therapy and central nervous system tumor risk: Large UK prospective study and meta-analysis International Journal of Cancer, November 7, 2014    Evidence Based Medicine

11 Effects of golden hour thrombolysis a Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) substudy JAMA Neurology, November 20, 2014    Clinical Article

12 Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi-stage, randomised, double-blind, placebo-controlled trial The Lancet Neurology, October 9, 2014    Clinical Article

13 The efficacy and safety of cilostazol in ischemic Stroke Patients with Peripheral Arterial Disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial International Journal of Stroke, November 18, 2014    Clinical Article

14 Neonatal vitamin D and childhood brain tumor risk International Journal of Cancer, November 17, 2014    Clinical Article

15 Emergency and critical care management of acute ischaemic stroke CNS Drugs, November 26, 2014    Clinical Article

16 Results of 2-year vitamin B treatment on cognitive performance: Secondary data from an RCT Neurology®, November 21, 2014    Clinical Article

17 Functional outcome after primary endovascular therapy or IV thrombolysis alone for stroke. an observational, comparative effectiveness study Cerebrovascular Diseases, November 24, 2014    Clinical Article

18 Dairy products and the risk of stroke and coronary heart disease: the Rotterdam Study European Journal of Nutrition, October 14, 2014    Clinical Article

19 Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women’s Health Initiative Memory Study Journal of the Academy of Nutrition and Dietetics, November 12, 2014    Clinical Article

20 The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT) The Lancet, October 30, 2014    Evidence Based Medicine    Clinical Article

Indexed Journals in Neurology: Current Opinion in Neurology, Stroke, Seizure, Cephalgia, Brain Injurymore